보건의료기술평가에서의 혁신과 가치
Innovation and Value in Health Technology Assessment
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
After reviewing discussions on the values to consider in the reimbursement decision-making for medical technologies, it was found that most consider factors such as the extent of health enhancement, unmet need, robustness of evidence, and disease severity, among others. These align with the criteria considered in drug reimbursement decision-making in Korea. There’s an ongoing debate about acknowledging benefits beyond quality-adjusted life years (QALY). Still, there remains a lack of discussions and consensus on measuring and incorporating these additional benefits. While some countries introduced a new mechanism of action as one of the value elements, none solely attributed value to it. Instead, they used it as an additional criterion, alongside conditions indicating health improvement, to categorize innovative drugs. Additionally, most countries did not evaluate innovation solely based on input factors. A range of domestic and international discussions should be considered in the debate over acknowledging the value of innovation in Korea.
Abstract
After reviewing discussions on the values to consider in the reimbursement decision-making for medical technologies, it was found that most consider factors such as the extent of health enhancement, unmet need, robustness of evidence, and disease severity, among others. These align with the criteria considered in drug reimbursement decision-making in Korea. There’s an ongoing debate about acknowledging benefits beyond quality-adjusted life years (QALY). Still, there remains a lack of discussions and consensus on measuring and incorporating these additional benefits. While some countries introduced a new mechanism of action as one of the value elements, none solely attributed value to it. Instead, they used it as an additional criterion, alongside conditions indicating health improvement, to categorize innovative drugs. Additionally, most countries did not evaluate innovation solely based on input factors. A range of domestic and international discussions should be considered in the debate over acknowledging the value of innovation in Korea.
참고문헌 (17)
- 신형주, "혁신가치 보상 위한 약가제도 개선 올해 내 발표될까", 메디칼업저버, ~ (2023)
- Brazier J, "The EQ-HWB : overview of the development of a measure of health and wellbeing and key results", Value Health, 25, pp.482~491 (2022)
- "Value Health", 2018, 131~139
- Hong J, "Risk preference and the value of hope in the treatment of severe illnesses", Korean J Health Econ Policy, 29, pp.45~66 (2023)
- Reed SD, "Quantifying value of hope", Value Health, 24, pp.1511~1519 (2021)
- Pinho-Gomes AC, "Evaluation of advanced therapy medicinal products by the national institute for health and care excellence(NICE) : an updated review", Pharmacoecon Open, 6, pp.147~167 (2022)
- Public preferences for health gains and cures: a discrete choice experiment (OHE consulting report), "Hampson G", Office of Health Economics, ~ (2019)
- Zhang M, "What is value in health and healthcare? A systematic literature review of value assessment frameworks", Value Health, 25, pp.302~317 (2022)
- Yuasa A, "Investigation of factors considered by health technology assessment agencies in eight countries", Pharmacoecon Open, 5, pp.57~69 (2021)
- Kwon SH, "Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea", Expert Rev Pharmacoecon Outcomes Res, 17, pp.411~419 (2017)
- Ministry of Health and Welfare, "2023 Korea innovative pharmaceutical company", Ministry of Health and Welfare, Korea Health Industry Development Institute, ~ (2023)
- 건강보험심사평가원, "약제의 요양급여대상여부 등의 평가기준및 절차 등에 관한 규정(규정 제467호, 2022.12.23)", 건강보험심사평가원, ~ (2022)
- "Guide to the methods of technology appraisal 2013" (2013)[URL]
- "The innovative medicines fund principles" (2022)[URL]
- 위험분담제도의 성과평가 및 발전방향 연구, "이태진", 서울대학교산학협력단·국민건강보험공단, ~ (2022)
- "What are the pricing and repricing mechanisms in Japan’s P&R system that pharma must understand when considering a launch in Japan?" (2023)[URL]
- Tanaka M, "Achievements and challenges of the Sakigake designation system in Japan", Br J Clin Pharmacol, 87, pp.4027~4035 (2021)